Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adjuvanted trivalent inactivated influenza vaccine + 23-valent pneumococcal polysaccharide vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination refers to the co-administration of an MF59-adjuvanted trivalent inactivated influenza vaccine (eTIV_a) and a 23-valent pneumococcal polysaccharide vaccine (PPV23). eTIV_a, marketed as Fluad, is an egg-derived vaccine designed to enhance the immune response in older adults (65+) against three strains of influenza (two A subtypes and one B lineage) by utilizing the MF59 oil-in-water emulsion adjuvant. PPV23, marketed as Pneumovax 23, provides protection against 23 serotypes of Streptococcus pneumoniae, which are responsible for the majority of invasive pneumococcal disease. Co-administration of these vaccines is a common clinical strategy to improve immunization coverage in the elderly, and clinical trials have demonstrated that simultaneous administration at separate sites is safe and maintains the immunogenicity of both vaccines.
- Brand names
- Fluad
- Other names
- eTIV_a + 23-valent pneumococcal polysaccharide vaccineeTIV_a + PPV23MF59-adjuvanted TIV + PPV23adjuvanted trivalent inactivated influenza vaccine + PPV23
02
Targets
HA (Hemagglutinin)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on adjuvanted trivalent inactivated influenza vaccine + 23-valent pneumococcal polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adjuvanted trivalent inactivated influenza vaccine + 23-valent pneumococcal polysaccharide vaccine.